Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines

Published:2023-04-18 Issue:5 Volume:14 Page:591-598
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Grabe Tobias¹^ORCID,Jeyakumar Kirujan¹^ORCID,Niggenaber Janina¹^ORCID,Schulz Tom¹^ORCID,Koska Sandra¹,Kleinbölting Silke¹,Beck Michael Edmund¹^ORCID,Müller Matthias P.¹^ORCID,Rauh Daniel¹^ORCID

Affiliation:

1. Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany

Funder

Bundesministerium f?r Bildung und Forschung

European Regional Development Fund

Deutsche Forschungsgemeinschaft

Ministerium f?r Kultur und Wissenschaft des Landes Nordrhein-Westfalen

Mercator Research Center Ruhr

IGNITE

Drug Discovery Hub Dortmund

EMODI

North Rhine-Westphalia

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00514

Reference30 articles.

1. Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

2. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

3. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

4. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

5. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Insights into the Binding Mode of a BLU-945 Analog with Wild-Type and Mutant EGFRs;Journal of Computational Biophysics and Chemistry;2024-03-16

2. Design and development of mutant EGFR inhibitors from a structural perspective;Indian Journal of Biochemistry and Biophysics;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3